Pregabalin for the treatment of neuropathic pain: a narrative review for primary care providers

References

• International Association for the Study of Pain Taxonomy. IASP. Available at: http://www.iasp-pain.org/Taxonomy#Neuropathicpain [Last accessed 22 February 2016]
   Google Scholar
• Gilron I, Baron R, Jensen T. Neuropathic pain: principles of diagnosis and treatment. Mayo Clin Proc 2015;90:532-45
   PubMed Web of Science ®Google Scholar
• Vranken JH. Mechanisms and treatment of neuropathic pain. Cent Nerv Syst Agents Med Chem 2009;9:71-8
   PubMedGoogle Scholar
• McCarberg B, D'Arcy Y, Parsons B, et al. Neuropathic pain: a narrative review of etiology, assessment, diagnosis, and treatment for primary care providers. Curr Med Res Opin. doi: 10.1080/03007995.2017.1321532
   Web of Science ®Google Scholar
• Stanos S, Brodsky M, Argoff C, et al. Rethinking chronic pain in a primary care setting. Postgrad Med 2016;128:502-15
   PubMed Web of Science ®Google Scholar
• Dowell D, Hargerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain – United States, 2016. Available at: http://www.cdc.gov/mmwr/volumes/65/rr/rr6501e1.htm. [Last accessed 26 May 2016]
   Google Scholar
• Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol 2015;14:162-73
   PubMed Web of Science ®Google Scholar
• Lyrica US prescribing information. Parke-Davis Div of Pfizer Inc. Available at: http://labeling.pfizer.com/ShowLabeling.aspx?id =561 [Last accessed 22 February 2016]
   Google Scholar
• Summary of Product Characteristics. Pfizer Limited. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003880/WC500166172.pdf [Last accessed 22 February 2016]
   Google Scholar
• Pfizer Press Release. Pfizer Japan Inc. Available at http://www.eisai.com/news/enews201311pdf.pdf [Last accessed 22 February 2016]
   Google Scholar
• Dooley DJ, Taylor CP, Donevan S, Feltner D. Ca2+ channel α2δ ligands: novel modulators of neurotransmission. Trends Pharmacol Sci 2007;28:75-82
   PubMed Web of Science ®Google Scholar
• Stahl SM, Porreca F, Taylor CP, et al. The diverse therapeutic actions of pregabalin: is a single mechanism responsible for several pharmacological activities? Trends Pharmacol Sci 2013;34:332-9
   PubMed Web of Science ®Google Scholar
• Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet 2010;49:661-9
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Tuchman M, LaMoreaux L, Sharma U. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004;110:628-38
   PubMed Web of Science ®Google Scholar
• Lesser H, Sharma U, LaMoreaux L, Poole RM. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial. Neurology 2004;63:2104-10
   PubMed Web of Science ®Google Scholar
• Richter RW, Portenoy R, Sharma U, et al. Relief of painful diabetic peripheral neuropathy with pregabalin: a randomized, placebo-controlled trial. J Pain 2005;6:253-60
   PubMed Web of Science ®Google Scholar
• Tolle T, Freynhagen R, Versavel M, et al. Pregabalin for relief of neuropathic pain associated with diabetic neuropathy: a randomized, double-blind study. Eur J Pain 2008;12:203-13
   PubMed Web of Science ®Google Scholar
• Arezzo JC, Rosenstock J, Lamoreaux L, Pauer L. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008;8:33
   PubMed Web of Science ®Google Scholar
• Satoh J, Yagihashi S, Baba M, et al. Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy: a 14 week, randomized, double-blind, placebo-controlled trial. Diabet Med 2011;28:109-16
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Corbin AE, Young JP Jr, et al. Pregabalin for the treatment of postherpetic neuralgia: a randomized, placebo-controlled trial. Neurology 2003;60:1274-83
   PubMed Web of Science ®Google Scholar
• Sabatowski R, Galvez R, Cherry DA, et al. Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain 2004;109:26-35
   PubMed Web of Science ®Google Scholar
• van Seventer R, Feister HA, Young JP Jr, et al. Efficacy and tolerability of twice-daily pregabalin for treating pain and related sleep interference in postherpetic neuralgia: a 13-week, randomized trial. Curr Med Res Opin 2006;22:375-84
   PubMed Web of Science ®Google Scholar
• Stacey BR, Barrett JA, Whalen E, et al. Pregabalin for postherpetic neuralgia: placebo-controlled trial of fixed and flexible dosing regimens on allodynia and time to onset of pain relief. J Pain 2008;9:1006-17
   PubMed Web of Science ®Google Scholar
• Siddall PJ, Cousins MJ, Otte A, et al. Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial. Neurology 2006;67:1792-800
   PubMed Web of Science ®Google Scholar
• Cardenas DD, Nieshoff EC, Suda K, et al. A randomized trial of pregabalin in patients with neuropathic pain due to spinal cord injury. Neurology 2013;80:533-9
   PubMed Web of Science ®Google Scholar
• van Seventer R, Bach FW, Toth CC, et al. Pregabalin in the treatment of post-traumatic peripheral neuropathic pain: a randomized double-blind trial. Eur J Neurol 2010;17:1082-9
   PubMed Web of Science ®Google Scholar
• Moon DE, Lee DI, Lee SC, et al. Efficacy and tolerability of pregabalin using a flexible, optimized dose schedule in Korean patients with peripheral neuropathic pain: a 10-week, randomized, double-blind, placebo-controlled, multicenter study. Clin Therapeut 2010;32:2370-85
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Strojek K, Griesing T, et al. Efficacy of pregabalin in neuropathic pain evaluated in a 12-week, randomised, double-blind, multicentre, placebo-controlled trial of flexible- and fixed-dose regimens. Pain 2005;115:254-63
   PubMed Web of Science ®Google Scholar
• Guan Y, Ding X, Cheng Y, et al. Efficacy of pregabalin for peripheral neuropathic pain: results of an 8-week, flexible-dose, double-blind, placebo-controlled study conducted in China. Clin Therapeut 2011;33:159-66
   PubMed Web of Science ®Google Scholar
• Vranken JH, Dijkgraaf MG, Kruis MR, et al. Pregabalin in patients with central neuropathic pain: a randomized, double-blind, placebo-controlled trial of a flexible-dose regimen. Pain 2008;136:150-7
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Turk DC, Wyrwich KW, et al. Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. J Pain 2008;9:105-21
   PubMed Web of Science ®Google Scholar
• Colton HR, Altevogt BM, eds. Sleep Disorders and Sleep Deprivation: An Unmet Public Health Problem. Washington DC: National Acadamies Press, 2006
   Google Scholar
• Benington JH, Heller HC. Restoration of brain energy metabolism as the function of sleep. Prog Neurobiol 1995;45:347-60
   PubMed Web of Science ®Google Scholar
• Holl RW, Hartman ML, Veldhuis JD, et al. Thirty-second sampling of plasma growth hormone in man: correlation with sleep stages. J Clin Endocrinol Metab 1991;72:854-61
   PubMed Web of Science ®Google Scholar
• Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive–behavioral clinical trials literature. Sleep Med Rev 2004;8:119-32
   PubMed Web of Science ®Google Scholar
• Roehrs T, Roth T. Sleep and pain: interaction of two vital functions. Semin Neurol 2005;25:106-16
   PubMed Web of Science ®Google Scholar
• Roth T, Arnold LM, Garcia-Borreguero D, et al. A review of the effects of pregabalin on sleep disturbance across multiple clinical conditions. Sleep Med Rev 2014;18:261-71
   PubMed Web of Science ®Google Scholar
• Roehrs TA. Does effective management of sleep disorders improve pain symptoms? Drugs 2009;69(Suppl 2):5-11
   PubMed Web of Science ®Google Scholar
• Boyle J, Eriksson ME, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012;35:2451-8
   PubMed Web of Science ®Google Scholar
• Hindmarch I, Dawson J, Stanley N. A double-blind study in healthy volunteers to assess the effects on sleep of pregabalin compared with alprazolam and placebo. Sleep 2005;28:187-93
   PubMed Web of Science ®Google Scholar
• Vinik A, Emir B, Parsons B, Cheung R. Prediction of pregabalin-mediated pain response by severity of sleep disturbance in patients with painful diabetic neuropathy and post-herpetic neuralgia. Pain Med 2014;15:661-70
   PubMed Web of Science ®Google Scholar
• Vinik A, Emir B, Cheung R, Whalen E. Relationship between pain relief and improvements in patient function/quality of life in patients with painful diabetic peripheral neuropathy or postherpetic neuralgia treated with pregabalin. Clin Therapeut 2013;35:612-23
   PubMed Web of Science ®Google Scholar
• Parsons B, Sanin L, Yang R, et al. Efficacy and safety of pregabalin in patients with spinal cord injury: a pooled analysis. Curr Med Res Opin 2013;29:1675-83
   PubMed Web of Science ®Google Scholar
• Navarro A, Saldana MT, Perez C, et al. Patient-reported outcomes in subjects with neuropathic pain receiving pregabalin: evidence from medical practice in primary care settings. Pain Med 2010;11:719-31
   PubMed Web of Science ®Google Scholar
• Anastassiou E, Iatrou CA, Vlaikidis N, et al. Impact of pregabalin treatment on pain, pain-related sleep interference and general well-being in patients with neuropathic pain: a non-interventional, multicentre, post-marketing study. Clin Drug Investig 2011;31:417-26
   PubMed Web of Science ®Google Scholar
• Bandelow B. Generalized Anxiety Disorder and Pain. Mod Trends Pharmacopsychiatry 2015;30:153-65
   PubMedGoogle Scholar
• Narasimhan M, Campbell N. A tale of two comorbidities: understanding the neurobiology of depression and pain. Ind J Psychiatry 2010;52:127-30
   PubMedGoogle Scholar
• Baldwin DS, den Boer JA, Lyndon G, et al. Efficacy and safety of pregabalin in generalised anxiety disorder: a critical review of the literature. J Psychopharmacol 2015;29:1047-60
   PubMed Web of Science ®Google Scholar
• Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs 2014;28:835-54
   PubMed Web of Science ®Google Scholar
• Stein MB, Sareen J. Clinical practice. Generalized anxiety disorder. N Engl J Med 2015;373:2059-68
   PubMed Web of Science ®Google Scholar
• Sharma U, Griesing T, Emir B, Young JP Jr. Time to onset of neuropathic pain reduction: a retrospective analysis of data from nine controlled trials of pregabalin for painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther 2010;17:577-85
   PubMed Web of Science ®Google Scholar
• Parsons B, Emir B, Knapp L. Examining the time to improvement of sleep interference with pregabalin in patients with painful diabetic peripheral neuropathy and postherpetic neuralgia. Am J Ther 2015;22:257-68
   PubMed Web of Science ®Google Scholar
• Cardenas DD, Emir B, Parsons B. Examining the time to therapeutic effect of pregabalin in spinal cord injury patients with neuropathic pain. Clin Therapeut 2015;37:1081-90
   PubMed Web of Science ®Google Scholar
• Parsons B, Emir B, Clair A. Temporal analysis of pain responders and common adverse events: when do these first appear following treatment with pregabalin. J Pain Res 2015;8:303-9
   PubMed Web of Science ®Google Scholar
• Emir B, Johnson K, Kuhn M, Parsons B. Predictive modeling of response to pregabalin for the treatment of neuropathic pain using 6-week observational data: a spectrum of modern analytics applications. Clin Therapeut 2017;39:98-106
   PubMed Web of Science ®Google Scholar
• Freynhagen R, Serpell M, Emir B, et al. A comprehensive drug safety evaluation of pregabalin in peripheral neuropathic pain. Pain Pract 2015;15:47-57
   PubMed Web of Science ®Google Scholar
• Cabrera J, Emir B, Dills D, et al. Characterizing and understanding body weight patterns in patients treated with pregabalin. Curr Med Res Opin 2012;28:1027-37
   PubMed Web of Science ®Google Scholar
• Bril V, England J, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathy: report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology 2011;76:1758-65
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy. Pain Pract 2014;14:167-84
   PubMed Web of Science ®Google Scholar
• Gilron I, Wajsbrot D, Therrien F, Lemay J. Pregabalin for peripheral neuropathic pain: a multicenter, enriched enrollment randomized withdrawal placebo-controlled trial. Clin J Pain 2011;27:185-93
   PubMed Web of Science ®Google Scholar
• Stacey BR, Dworkin RH, Murphy K, et al. Pregabalin in the treatment of refractory neuropathic pain: results of a 15-month open-label trial. Pain Med 2008;9:1202-8
   PubMed Web of Science ®Google Scholar
• Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study” – a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013;154:2616-25
   PubMed Web of Science ®Google Scholar
• Schug SA, Parsons B, Almas M, Whalen E. Effect of concomitant pain medications on response to pregabalin in patients with postherpetic neuralgia or spinal cord injury-related neuropathic pain. Pain Physician 2017;20:E53-63
   PubMed Web of Science ®Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 2010;17:1113-88
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 2010;85(3 Suppl):S3-S14
   PubMed Web of Science ®Google Scholar